Aurobindo Pharma Targets 10,000 Metric Tonnes Annual Penicillin-G Production Amid Government Policy Support
Key Insights
Aurobindo Pharma plans to ramp up Penicillin-G (search) production to over 10,000 metric tonnes annually within 12 months, with its Kakinada facility ultimately targeting 15,000 metric tonnes capacity.
The company's China manufacturing plant is expected to reach EBITDA break-even in Q4 and contribute meaningfully to bottom-line EBITDA next year.
Government relaxation on minimum import prices for Pen-G, 6 APA (search), and Amoxicillin is viewed as a strategic catalyst for India's antibiotic self-reliance.
Aurobindo Pharma is accelerating its Penicillin-G (search) production capabilities, with plans to exceed 10,000 metric tonnes on an annual basis over the next 12 months, according to CFO S Subramanian. The Hyderabad-based pharmaceutical company's strategic expansion comes as it positions itself to capitalize on government policy changes supporting domestic antibiotic manufacturing.
Production Expansion and Facility Development
The company's Pen-G facility, located in a Special Economic Zone at Kakinada in Andhra Pradesh, is progressing toward its ultimate production capacity of 15,000 metric tonnes per annum. "The ramp-up of the facility (Pen-G) is progressing in line with expectations and is well-positioned to deliver a meaningful uplift in profitability over time," Subramanian told analysts during a recent call.
The CFO emphasized that yield levels are steady and improving consistently over time, indicating operational efficiency gains as production scales up. This expansion represents a structurally important initiative that will enhance cost competitiveness, reduce external dependencies, and strengthen margins over time.
Government Policy Support
Aurobindo Pharma has welcomed the central government's decision to provide one-year relaxation on minimum import prices for Pen-G, 6 APA (search), and Amoxicillin. Subramanian described this policy change as "a very important and positive catalyst event for the company," noting its strategic importance for creating India's self-reliance in antibiotics and reducing supply disruption risks.
"We consider this decision by the Government strategically important for creating India's self-reliance in antibiotics and reducing supply disruption risks and will boost the domestic manufacturing of APIs and KSMs," Subramanian stated.
Global Operations Progress
The company's OSD China facility continues advancing toward an annual capacity of 2 billion units, currently supported by EU approval for 10 products and 3 local product approvals. Subramanian expressed confidence in achieving EBITDA break-even in the fourth quarter and meaningful contribution to bottom-line EBITDA in the following year.
In the United States, Aurobindo is entering what Subramanian characterized as "an important phase of growth." The Dayton facility has successfully transitioned into commercial phase with manufacturing underway and is expected to begin contributing revenues significantly from FY27 onwards. The Raleigh facility remains on track pending regulatory clearance, with the company fully prepared to scale up operations.
Strategic Focus and Financial Performance
Looking ahead, the company's growth strategy centers on building differentiated product portfolios with increasing focus on complex generics across dermal, transdermal, nasal, respiratory, and oncology therapeutic areas. With manufacturing capacity exceeding 60 billion units and further expansion underway, Aurobindo is positioned to support rising demand across various markets while improving operating leverage.
For the third quarter ended December 31, 2025, Aurobindo Pharma reported revenue from operations of ₹8,646 crore compared with ₹7,979 crore in the year-ago period. The company maintains confidence in achieving its internal EBITDA margin target of 20-21% for FY26.
Market Position and Outlook
Aurobindo Pharma's P/E ratio stands at approximately 19.17x as of February 2026, notably lower than the industry average P/E of 26.5x for the Indian Pharmaceuticals sector and favorably comparing to the peer average of 45.8x. The company's market capitalization is around ₹67,303 crore.
Analysts hold a generally positive view with a consensus rating of 'Buy' and an average 12-month price target of approximately ₹1,345.19 from 27 analysts, suggesting upside potential of over 16%. Forecasts indicate revenue growth accelerating to 10.0% annually through 2027, outpacing historical growth rates.